Kimball Electronics, Inc. First Quarter Fiscal Year 2027 Financial Results - KIMBALL ELECTRONICS INC

Explicit Guidance:

• Fiscal 2027 Full-Year Net Sales: Reiterated guidance expected at the high end of the range, $1.535 billion to $1.560 billion, driven by strength in the medical vertical.
• Fiscal 2027 Adjusted Operating Margin: Expected to be 4.4% to 4.7% of net sales; management notes margins are currently impacted by material inflation and new facility ramp but expects them to hold.
• Fiscal 2027 Capital Expenditures (Capex): Forecasted range of $50 million to $60 million.
• Fiscal 2027 Effective Tax Rate: Expects the rate to be in the "low 30s" for the full year, excluding the one-time impact of withholding taxes from cash repatriation used to fund the Helboon (HealthWet) acquisition.

Business-Segment Outlook:

• Medical: Anticipating double-digit growth for the remainder of the fiscal year, building on Q1's 9% organic increase; open orders for the segment are expected to reflect continued strength.
• Automotive: Organic growth driven by "steering" components (over 70% of segment), specifically the ramp-up of a new program in Poland and early production transfer preparations in China; Q1 growth was 4% but may face margin pressure from component inflation.
• Industrial: Expects continued organic growth with strength in off-highway equipment, factory automation, public safety, and smart metering.
• Climate Control: Currently facing demand weakness in HVAC systems (primarily North America); management views this as an opportunity to leverage electronics manufacturing and high-level assembly expertise for future growth.
• Helboon (HealthWet) Acquisition: Integration progressing on plan and budget; revenue expected to ramp over the course of fiscal 2027. Synergies and top-line growth are the primary focus.

Market and Competitive Outlook:

• Supply Chain Dynamics: Electronic components (specifically memory) are tight, impacting the Automotive and Industrial segments with cost pressures; Medical segment less affected due to focus on full assembly and molded plastics rather than pure PCBA.
• Customer Interest: Rising interest from new and existing customers in the combined medical CDMO platform; the company is using AI-driven data mining tools to identify real-time opportunities.
• Rebranding: Plans to rebrand the entire company to "Kimball Solutions" following shareholder vote approval at the annual meeting (next week), completing a phased rollout; intended to signal shift beyond traditional EMS to comprehensive solutions including design, supply chain, and precision molding.

Macro / Industry Outlook:

• Currency: Foreign exchange provided a 1% favorable impact on Q1 consolidated sales.
• Inflation: Management anticipates continued inflationary pressure on material component costs, particularly in Automotive and Industrial, which could impact revenue margins if not offset by price increases.
• US Economic Conditions: North American market remains sluggish in automotive due to lower EV demand; however, the broader medical vertical shows broad-based strength across all geographies.

Strategic Initiatives:

• Indianapolis Facility: Production expected to start in December 2026; equipment movement and qualification are on schedule and on budget. The facility will support the enhanced medical CDMO platform with available capacity.
• Business Development Enhancements: Expansion of the responsibilities of the Helboon CEO and team to sharpen business development efforts in the medical CDMO space.
• Capacity Expansion: The Indianapolis move and acquisition of Helboon position the company for growth in high-level product assemblies and design/engineering support.

Risks and Headwinds to Outlook:

• Margin Pressure: Risk of margin compression in the short term due to higher material component costs, the ramp-up of the Indianapolis facility, and potential inflation in the Automotive/Industrial segments.
• Tax Rate Volatility: The Q1 effective tax rate (66.1%) was an anomaly due to withholding taxes on cash repatriation; while the full-year rate is forecast at the low 30s, the company acknowledges this is still higher than normal and is working to reduce it.
• Acquisition Integration: While integration is on track, management cautions that growing the medical CDMO business "takes time" and that program ramp-up cycles can be lengthy.
• Inventory: Inventory levels increased by approximately $40 million quarter-over-quarter to support future growth and longer lead times; conversion days remain at a multi-year low (82 days).

Management Tone on the Future:

• Confidence Level: High confidence in the strategic fit and growth trajectory of the Helboon acquisition, with excitement described as "higher now than ever."
• Forward-Looking Stance: Management is reiterating guidance at the high end of the range, indicating positive momentum, particularly in core medical, despite macro headwinds in specific sectors.
• Strategic Shift: Strong commitment to transitioning the business model toward a full-service "solutions" provider (Kimball Solutions) rather than traditional EMS.

Miscellaneous:

• Share Repurchases: $3.1 million invested in Q1 to repurchase 127,000 shares; total returned to shareholders since 2015 is $118.6 million.
• Liquidity: Cash and equivalents of $72.8 million; short-term liquidity (cash + unused credit facilities) totaled $270.8 million as of September 30, 2026.
• Cash Flow: Cash used in operating activities was $19.3 million, primarily driven by inventory build-out to support growth trajectory.